NCT02818582: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02818582 |
|---|---|
| Title | PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 1, 2016 |
| Completion date | Aug. 31, 2020 |
| Required reporting date | Aug. 31, 2021, midnight |
| Actual reporting date | Aug. 25, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |